Further research into the rate of EGFR mutations, the outcomes of various treatment methods, and the safety and complication rates of various biopsy procedures among our lung cancer population, as well as effects of time and experience of the operator on the quality of specimens obtained for molecular analysis is much needed in Trinidad and Tobago. The gene discussed is EGFR; the disease is lung carcinoma.